Toll-like receptor agonists as third signals for dendritic cell-tumor fusion vaccines

Head and Neck

Volumn 32, Issue 6, 2010, Pages 700-707

  Cho, Edward I ^a   Tan, Chunrui ^b   Koski, Gary K ^a   Cohen, Peter A ^c   Shu, Suyu ^d   Lee, Walter T ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c MAYO CLINIC   (United States)

^d EARLE A CHILES RESEARCH INSTITUTE   (United States)

Author keywords

Dendritic cells; Electrofusion; Third signal; Toll like receptor agonists; Tumor immunology

Indexed keywords

CYTOSINE; CYTOSINE PHOSPHATE GUANINE; DENDRITIC CELL VACCINE; GUANINE; INTERLEUKIN 12; INTERLEUKIN 12P70; PHOSPHATE; POLYINOSINIC POLYCYTIDYLIC ACID; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CPG ISLAND; CYTOKINE PRODUCTION; DRUG EFFICACY; ELECTROFUSION (CELL); ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; INGUINAL LYMPH NODE; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN METASTASIS; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR IMMUNOLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CELL FUSION; DENDRITIC CELLS; ELECTRIC STIMULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HYBRID CELLS; IMMUNOTHERAPY; INTERLEUKIN-12; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; RECOMBINANT FUSION PROTEINS; SPECIFIC PATHOGEN-FREE ORGANISMS; TOLL-LIKE RECEPTORS; VACCINES, SYNTHETIC;

EID: 77952775235     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21241     Document Type: Article

References (14)

1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-252.
2. Hayashi T, Tanaka H, Tanaka J, et al. Immunogenicity and therapeutic efficacy of dendritic-tumor hybrid cells generated by electrofusion. Clin Immunol 2002;104:14-20. (Pubitemid 34856504)
3. Kjaergaard J, Shimizu K, Shu S. Electrofusion of syngeneic dendritic cells and tumor generates potent therapeutic vaccine. Cell Immunol 2003;225:65-74. (Pubitemid 38091551)
4. Lee WT, Shimizu K, Kuriyama H, Tanaka H, Kjaergaard J, Shu S. Tumor-dendritic cell fusion as a basis for cancer immunotherapy. Otolaryngol Head Neck Surg 2005;132:755-764. (Pubitemid 40692621)
5. Shu S, Zheng R, Lee WT, Cohen PA. Immunogenicity of dendritic-tumor fusion hybrids and their utility in cancer immunotherapy. Crit Rev Immunol 2007;27:463-483.
6. Rehli M. Of mice and men: species variations of Toll-like receptor expression. Trends Immunol 2002;23:375-378.
7. Reis e Sousa C. Toll-like receptors and dendritic cells: for whom the bug tolls. Semin Immunol 2004;16:27-34.
8. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002;20:709-760.
9. Kadowaki N, Ho S, Antonenko S, et al. Subsets of human dendritic cell precursors express different Toll-like receptors and respond to different microbial antigens. J Exp Med 2001;194:863-869.
10. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 2005;6:769-776.
11. Stanley MA. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol 2002;27:571-577.
12. Zheng R, Cohen PA, Paustian CA, et al. Paired Toll-like receptor agonists enhance vaccine therapy through induction of interleukin-12. Cancer Res 2008;68:4045-4049.
13. Tanaka H, Shimizu K, Hayashi T, Shu S. Therapeutic immune response induced by electrofusion of dendritic and tumor cells. Cell Immunol 2002;220:1-12.
14. Pilon-Thomas S, Li W, Briggs JJ, Djeu J, Mule JJ, Riker AI. Immunostimulatory effects of CpG-ODN upon dendritic cell-based immunotherapy in a murine melanoma model. J Immunother 2006;29:381-387.